Gastroesophageal refl ux disease and irritable bowel syndrome overlapping: unresolved issues
https://doi.org/10.30629/0023-2149-2020-98-9-10-645-649
Abstract
The review presents literature data concerning the rate and clinical features in cases of the gastroesоphageal refl ux disease (GERD) and irritable bowel syndrome (IBS )overlapping. The mean rate of GERD and IBS overlapping is 36–48 .8%, but in individual articles varies from 8–11% to 71–79%. A signifi cant variation in the rate is explained by diff erent approaches to the diagnosis of GERD and IBS in various studies (use of questionnaires, endoscopic examination, esophageal pH-impedancemetry). The high rate of GERD and IBS overlapping is related to the common pathogenetic mechanisms of both diseases (disorders оf gastrointestinal motility, visceral hypersensitivity). The features of the clinical picture and treatment in cases of GERD and IBS overlapping are studied insuffi ciently and require further research.
About the Authors
A. A. Sheptulin
First Moscow State Medical University named after Sechenov I.M. (Sechenov University)
Russian Federation
Russian Federation
Arkady A. Sheptulin — MD, PhD, DSc, Professor Departament of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Medical faculty
119991, Moscow
K. E. Vinogradskaya
First Moscow State Medical University named after Sechenov I.M. (Sechenov University)
Russian Federation
Russian Federation
119991, Moscow
References
1. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Ye.K. , Dronova О.B., Zayratyants О.V., Sayfutdinov R.G., Sheptulin A.A., Lapina T.L., Pirogov S.S., Kucheryavy Yu.A., Storonova O.A., Andreyev D.N. Diagnostics and treatment of gastroesophageal refl ux disease: clinical guidelines of the Russian gastroenterological association. Rossiskii. Zhurnal. Gastroenterologii., Gepatoljgii, Koloproctologii. 2017;27(4):75–95. (in Russian). DOI: 10.22416/1382-4376-2017-27-4-75-95
2. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller M. Bowel Disorders. Gastroenterology. 2016;150:1393–1407. DOI: 10.1053/j.gastro.2016.02.031
3. Nastaskin I., Mehdikhani E., Conklin J., Park S., Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig. Dis. Sci. 2006;51(12):2113–2120. DOI: 10.1007/s10620-006-9306-y
4. Lovell R.M., Ford A.C. Prevalence of gastro-esophageal refl ux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am. J. Gastroenterol. 2012;107(12):1793–1801. DOI: 10.1038/ajg.2012.336
5. De Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal refl ux disease with irritable bowel syndrome. World J. Gastroenterol. 2013;19(35):5787–5797. DOI: 10.3748/wjg.v19.i35.5787
6. Neumann H., Mönkemüller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett’s esophagus. Dig. Dis. 2008;26(3):243–247. DOI: 10.1159/000121354
7. Noh Y.W., Jung H.-K., Kim S.-E., Jung S.-A. Оverlap of erosive and non-erosive refl ux diseases with functional gastrointestinal disorders according to Rome III criteria. J. Neurogastroenterol. Motil. 2010;16(2):148-156. DOI: 10.5056/jnm.2010.16.2.148
8. Nam S.Y., Ryu K.H., Park B.J. Irritable bowel syndrome is associa ted with gastroesophageal refl ux symptom but not erosive esophagitis. J. Neurogastroenterol. Motil. 2013;19(4):521–531. DOI: 10.5056/jnm.2013.19.4.521
9. Nagasako C.K., Garcia Montes C., Silva Lorena S.L., Mesquita M.A. Irritable bowel syndrome subtypes: clinical and psychological features, body mass index and comorbidities. Rev. Esp. Enferm. Dig. 2016;108 (2):59–64. DOI: 10.17235/reed.2015.3979/2015
10. El-Salhy M., Gilja O.D., Hatlebakk J.G. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol. Med. Rep. 2019;20(1):787–794. DOI: 10.3892/mmr.2019.10284
11. Lee K.J., Kwon H.C., Cheong J.Y., Cho S.W. Demographic, clinical, and psychological characteristics of the heartburn groups classifi ed using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal refl ux disease group. Digestion. 2009;79(3):131–136. DOI: 10.1159/000209848
12. Martinucci I., de Bortoli N., Di Fluri G., Mismas V., Gambaccini D,. Leonardi G,. Bellini M., Marchi S.P. Diagnosis of NERD in a population of patients with and without IBS: a pH-MII study. Digestive and Liver Disease. 2011;43(3):168.
13. Fujiwara Y., Kubo M., Kohata Y., Machida H., Okazaki H., Yamagami H. et al. Cigarette smoking and its association with overlapping gastroesophageal refl ux disease, functional dyspepsia, or irritable bowel syndrome. Intern. Med. 2011;50(21):2443–2447. DOI: 10.2169/internalmedicine.50.6012
14. Lee Y.J., Park K.S. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J. Gastroenterol. 2014;20(10):2456–69. DOI: 10.3748/wjg.v20.i10.2456
15. DuPont A.W., Jiang Z.-D., Harold S.A., Snyder N., Galler G.W. Garcia Torres F., DuPont H.L. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89(2):119–23. DOI: 10.1159/000356314
16. Simren M., Törbblom H., Palsson O.S., Van Tilburg V.A.L., Van Oudenhove L., Tack J. Whitehead W.E. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent fi ndings from fi ve diff erent patients. Gut. 2018;67(2):255– 262. DOI: 10.1136/gutjnl-2016-312361
17. Kanazawa M., Hongo M., Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2011;26(3):119–21. DOI: 10.1111/j.1440-1746.2011.06640.x
18. Deiteren A., De Wit A., Van der Linden L., De Man J.G., Pelckmans P.A., De Winter B.Y. Irritable bowel syndrome and visceral hypersensitivity : risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg. 2016;79(1):29–38
19. Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive refl ux disease. Gut. 2008;57(5):674–683. DOI: 10.1136/gut.2007.127886
20. Katzka D.A., Pandolfi no D.A., Kahrilas P.J. Phenotypes of gastroesophageal refl ux disease: where Rome, Lyon and Montreal meet. Clin. Gastroenterol. Hepatol. 2020;18(4):767–776. DOI: 10.1016/j.cgh.2019.07.015
21. Rubenstein J.H., Nojkov B., Korsnes S., Adlis S.A., Shaw M.J., Weinman B. et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2007;26:443–452. DOI: 10.1111/j.1365- 2036.2007.03393.x
22. Hsu C.S., Liu T.T., Wen S.H., Wang C.C., Yi C.H., Chen J.H. et al. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal refl ux disease overlap with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2015;27(5):516–522. DOI: 10.1097/MEG.0000000000000334
23. Lei W.Y., Chang W.C., Wen S.H., Wong M.W., Hung J.S., Yi C.H. et al. Impact of concomitant dyspepsia and irritable bowel syndrome on symptom burden in patients with gastroesophageal refl ux disease. J. Formos. Med. Assoc. 2019;118(4):797–806. DOI: 10.1016/j.jfma.2018.12.002
24. Funaki Y., Kaneko H., Rawamura Y., Yoshimine T., Tamura Y., Izawa Sh. et al. Impact of comorbid irritable bowel syndrome on reatment outcome in non-erosive refl ux disease on long-term proton pump inhibitor in Japan. Digestion. 2017;96(1):39–45. DOI: 10.1159/000477801
25. Lee S.Y., Lee K.J., Kim S.J., Sung W.H. Prevalence and risk factors for overlaps between gastroesophageal refl ux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. DOI: 10.1159/000211715
26. De Vries D.R., Van Herwaarden M.A., Baron A., Smout A.J.P.M., Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal refl ux disease. Scand. J. Gastroenterol. 2007;42(8):951–956. DOI: 10.1080/00365520701204204
27. Lacy B., Ayyagari R., Guerin A, Lopez A., Shi S., Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap. Adv. Gastroenterol. 2019;12:1756284818818326. DOI: 10.1177/1756284818818326
28. Lee S.W., Chang C.S., Lien H.C., Peng Y.C., Wu C.Y., Yeh H.Z. Impact of overlapping functional gastrointestinal disorders on the presentation and quality of life in patients with erosive esophagitis and nonerosive refl ux disease. Med. Princ. Pract. 2015;24(5):491–495. DOI: 10.1159/000431370
29. Zerbib F., Belhocine K., Simon M., Cardepont M., Mion F., Bruley des Varannes S., Galmiche J.-P. Clinical, but not oesophageal pH-impedance, profi les predict response to proton pump inhibitors in gastro-oesophageal refl ux disease. Gut. 2012;61(4):501–506. DOI: 10.1136/gutjnl-2011-300798
30. Garros A., Mion F., Marjoux S., Damon H., Roman S. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring. Dis. Esophagus. 2016;29(7):787–793. DOI: 10.1111/dote.12374
31. Wu J.C., Lai L.H., Chow D.K., Wong G.L., Sung J.J., Chan F.K. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal refl ux disease. Neurogastroenterol. Motil. 2011;23(2):155–160.e31. DOI: 10.1111/j.1365-2982.2010.01627.x
32. Guillemot F., Ducrotté P., Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal refl ux disease in general practice. Gastroenterol. Clin. Biol. 2005;29(3):243–246. DOI: 10.1016/s0399-8320(05)80756-0
33. Mönnikes H., Schwan T., van Rensburg C., Straszak A., Theek C., Sander P., Lühmann P. Randomized clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suff ering from an overlap with erosive gastro-oesophageal refl ux disease. Aliment. Pharmacol. Ther. 2012;35(11):1279–1289. DOI: 10.1111/j.1365-2036.2012.05085.x
34. Raftopoulos Y., Papasavas P., Landreneau R., Hayetian F., Santucci T., Gagne D. et al. Clinical outcome of laparoscopic antirefl ux surgery for patients with irritable bowel syndrome. Surg. Endosc. 2004;18(4):655–659. DOI: 10.1007/s00464-003-8162-5
35. Gasiorowska A., Poh C.H., Fass R. Gastroesophageal refl ux disease (GERD) and irritable bowel syndrome (IBS) — is it one disease or an overlap of two disorders? Dig. Dis. Sci. 2009;54(9):1829–1834. DOI: 10.1007/s10620-008-0594-2
36. De Bortoli N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E. et al. Gastroesophageal refl ux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann. Gastroenterol. 2018;31(6):639–648. DOI: 10.20524/aog.2018.0314
37. Vaezi M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. Epub 2017 May 19. DOI: 10.1053/j.gastro.2017.04.047
Review
For citations:
Sheptulin A.A., Vinogradskaya K.E. Gastroesophageal refl ux disease and irritable bowel syndrome overlapping: unresolved issues. Clinical Medicine (Russian Journal). 2020;98(9-10):645-649. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-9-10-645-649
Views:
834
Email this article 